News

  • 1 October 2017

    Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the treatment of patients with Wilson Disease, have been accepted for poster presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC, October 20-24, 2017.

  • 18 September 2017

    Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announced an investment from the Bill & Melinda Gates Foundation to support the development of Immunocore’s soluble TCR-based therapeutics for infectious diseases.

  • 18 September 2017

    Sonendo, Inc., a leading dental technology company, announced today that General Atlantic, a leading global growth equity firm, has made a strategic investment in the company. General Atlantic will be joining existing investors Fjord Ventures, OrbiMed Advisors LLC, Meritech Capital Partners, CVF LLC, and NeoMed to lead the company's latest fundraising round valued at $50 million. In its next phase of growth, Sonendo plans to accelerate ongoing commercialization efforts and further expand and diversify its current product portfolio.

  • 13 September 2017

    Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced the presentation of positive results from its prospective, multicenter clinical study at the 2017 International Continence Society (ICS) Congress in Florence, Italy.

  • 13 September 2017

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.